Shigella 4V2
Alternative Names: Shigella Bioconjugate Vaccine - LimmaTech Biologics; Shigella-4V2Latest Information Update: 26 Nov 2024
Price :
$50 *
At a glance
- Originator LimmaTech Biologics
- Class Bacterial vaccines; Conjugate vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Shigella infections
Most Recent Events
- 12 Nov 2024 Phase-II clinical trials in Shigella infections (Prevention) in USA (IM) (NCT06615375)
- 04 Oct 2024 LimmaTech Biologics plans the phase II S4V03 trial for Shigella infections in October 2024 (NCT06615375)
- 29 Jul 2024 Preclinical trials in Shigella infections in Switzerland (Parenteral)